CN100503611C - 特定环木脂体的新用途 - Google Patents

特定环木脂体的新用途 Download PDF

Info

Publication number
CN100503611C
CN100503611C CNB028161904A CN02816190A CN100503611C CN 100503611 C CN100503611 C CN 100503611C CN B028161904 A CNB028161904 A CN B028161904A CN 02816190 A CN02816190 A CN 02816190A CN 100503611 C CN100503611 C CN 100503611C
Authority
CN
China
Prior art keywords
igf
cell
picropodophyllin
cancer
podophyllotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028161904A
Other languages
English (en)
Chinese (zh)
Other versions
CN1543466A (zh
Inventor
奥利·拉森
马格努斯·阿克塞尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axelar AB
Original Assignee
Axelar AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axelar AB filed Critical Axelar AB
Publication of CN1543466A publication Critical patent/CN1543466A/zh
Application granted granted Critical
Publication of CN100503611C publication Critical patent/CN100503611C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028161904A 2001-06-19 2002-06-19 特定环木脂体的新用途 Expired - Fee Related CN100503611C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE01021682 2001-06-19
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds
US30043101P 2001-06-26 2001-06-26
US60/300,431 2001-06-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2009101347598A Division CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途

Publications (2)

Publication Number Publication Date
CN1543466A CN1543466A (zh) 2004-11-03
CN100503611C true CN100503611C (zh) 2009-06-24

Family

ID=20284528

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB028161904A Expired - Fee Related CN100503611C (zh) 2001-06-19 2002-06-19 特定环木脂体的新用途
CNA2009101347598A Pending CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途
CN028162404A Pending CN1659171A (zh) 2001-06-19 2002-06-19 新用途或环木脂体以及新环木脂体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2009101347598A Pending CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途
CN028162404A Pending CN1659171A (zh) 2001-06-19 2002-06-19 新用途或环木脂体以及新环木脂体

Country Status (15)

Country Link
US (7) US7348358B2 (https=)
EP (5) EP1498121B1 (https=)
JP (2) JP2004534078A (https=)
KR (1) KR100940055B1 (https=)
CN (3) CN100503611C (https=)
AT (1) ATE441411T1 (https=)
AU (2) AU2002314671B2 (https=)
CA (2) CA2451047C (https=)
DK (1) DK1498121T3 (https=)
ES (1) ES2333014T3 (https=)
NO (1) NO332642B1 (https=)
NZ (2) NZ530172A (https=)
PT (1) PT1498121E (https=)
SE (1) SE0102168D0 (https=)
WO (2) WO2002102805A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0203747D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP1732898B1 (en) 2004-03-12 2008-01-23 Analytecon S.A. Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
AU2007218217A1 (en) * 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof
WO2009108857A2 (en) * 2008-02-27 2009-09-03 Combithera, Inc. Combination therapy for prostate cancer
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
WO2010138686A1 (en) * 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
US7924203B2 (en) * 2009-06-12 2011-04-12 Analog Devices, Inc. Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5642283B2 (ja) * 2010-08-31 2014-12-17 アクセラー エービー シクロリグナンを調製するための新たな方法
SG189295A1 (en) 2010-10-08 2013-05-31 Axelar Ab Picropodophyllin polymorphs b or c for use in cancer therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP5892508B2 (ja) * 2011-05-23 2016-03-23 国立大学法人 鹿児島大学 抗腫瘍剤及びその製造方法
WO2013124382A1 (en) * 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of cardiovascular disorders
WO2013132263A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives for use in therapy
WO2013132262A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
WO2014102889A1 (ja) * 2012-12-25 2014-07-03 国立大学法人鹿児島大学 抗腫瘍剤及びその製造方法
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
CA2912254C (en) * 2013-05-10 2021-06-08 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN106937529B (zh) 2015-10-27 2021-02-05 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
CN110669054B (zh) * 2018-07-03 2022-04-26 南京药石科技股份有限公司 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途
KR102378151B1 (ko) 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control
EP0207124B1 (en) * 1984-12-28 1991-10-09 Conpharm Ab Use of podophyllotoxin and derivatives thereof
NO170760C (no) 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
SE468213B (sv) * 1986-06-27 1992-11-23 Conpharm Ab Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit
KR890700023A (ko) * 1986-11-19 1989-03-02 케맥스 파마슈우티칼스 인코포레이티드 리폭시게나제 저해제
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1075316A (zh) 1992-10-22 1993-08-18 布里斯托尔-米尔斯·斯奎布公司 表鬼臼毒中间体的制备方法
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
JPH09194368A (ja) * 1996-01-11 1997-07-29 Pola Chem Ind Inc ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤
US5726027A (en) 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
US7020563B1 (en) * 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
WO2000000238A1 (en) 1998-06-26 2000-01-06 Quanam Medical Corporation Topoisomerase inhibitors for prevention of restenosis
WO2001052826A2 (en) * 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
ATE339423T1 (de) * 2000-11-20 2006-10-15 Song-Bae Kim Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
antineoplastic and antiviral. marina gordaliza.arch pharm,Vol.327 No.3. 1994 *
cytotoxic constituents from. miriam novelo.journal of natural products,Vol.56 No.10. 1993 *
cytotoxic cyclolignans related to. marina gordaliza.ill farmaco,Vol.56 No.4. 2001 *
methyl ethera of. j.m.miguel.journal of natural products,Vol.58 No.6. 1995 *

Also Published As

Publication number Publication date
US7629381B2 (en) 2009-12-08
KR20040007743A (ko) 2004-01-24
SE0102168D0 (sv) 2001-06-19
NO20035648D0 (no) 2003-12-17
JP5071910B2 (ja) 2012-11-14
KR100940055B1 (ko) 2010-02-04
US20060154982A1 (en) 2006-07-13
US7709526B2 (en) 2010-05-04
WO2002102805A1 (en) 2002-12-27
EP2186513A1 (en) 2010-05-19
WO2002102804A1 (en) 2002-12-27
EP1938819A2 (en) 2008-07-02
EP1938818A3 (en) 2010-04-07
DK1498121T3 (da) 2009-12-14
JP2005500300A (ja) 2005-01-06
US20040186169A1 (en) 2004-09-23
AU2002311731B8 (en) 2009-10-29
NO332642B1 (no) 2012-11-26
EP1938818A2 (en) 2008-07-02
PT1498121E (pt) 2009-12-04
ES2333014T3 (es) 2010-02-16
US20090326248A1 (en) 2009-12-31
NZ530172A (en) 2004-12-24
CA2451047A1 (en) 2002-12-27
ATE441411T1 (de) 2009-09-15
US8389747B2 (en) 2013-03-05
JP2004534078A (ja) 2004-11-11
CA2451047C (en) 2012-10-09
NZ530290A (en) 2005-05-27
CN1659171A (zh) 2005-08-24
US20040167208A1 (en) 2004-08-26
US20100216728A1 (en) 2010-08-26
CA2455328C (en) 2011-09-20
EP1397369A1 (en) 2004-03-17
EP1498121B1 (en) 2009-09-02
EP1498121A1 (en) 2005-01-19
WO2002102804A8 (en) 2004-05-13
AU2002311731B2 (en) 2009-02-26
US20080119528A1 (en) 2008-05-22
US20080221207A1 (en) 2008-09-11
US7348358B2 (en) 2008-03-25
US7662851B2 (en) 2010-02-16
CN1543466A (zh) 2004-11-03
AU2002311731C1 (en) 2009-09-03
NO20035648L (no) 2004-02-18
CN101606929A (zh) 2009-12-23
CA2455328A1 (en) 2002-12-27
AU2002314671B2 (en) 2008-09-18
EP1938819A3 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
CN100503611C (zh) 特定环木脂体的新用途
AU2002311731A1 (en) New use of specific cyclolignans
Mereyala et al. Cytotoxic activity of styryl lactones and their derivatives
AU2002314671A1 (en) New use of cyclolignans and new cyclolignans
AU2009201542B2 (en) New use of specific cyclolignans
RU2428425C2 (ru) Противоопухолевые соединения
CN109045012A (zh) 新骨架螺环倍半萜二聚体化合物的应用
EP1397368A1 (en) New use of specific cyclolignans
CN109053651A (zh) 一种新骨架螺环倍半萜二聚体化合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOVITRUM AB

Free format text: FORMER OWNER: AXELAR AB

Effective date: 20041217

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20041217

Address after: Stockholm

Applicant after: Biovitrum AB

Address before: Stockholm

Applicant before: Axelar AB

ASS Succession or assignment of patent right

Owner name: AXELAR AB

Free format text: FORMER OWNER: BIOVITRUM AB

Effective date: 20060421

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060421

Address after: Stockholm

Applicant after: Axelar AB

Address before: Stockholm

Applicant before: Biovitrum AB

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090624

Termination date: 20190619

CF01 Termination of patent right due to non-payment of annual fee